Critical role of NF-κB in pancreatic cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Lakshmi Prabhu 1 , Rasika Mundade 1 , Murray Korc 2, 3 , Patrick J. Loehrer 4 , Tao Lu 1, 3, 5 1 Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA 2 Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA 3 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA 4 Division of Hematology and Oncology, Indiana Cancer Pavilion, Indianapolis, IN, USA 5 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA Correspondence to: Tao Lu, e-mail: lut@iupui.edu Keywords: NF-κB, pancreatic cancer Received: August 26, 2014 Accepted: October 23, 2014 Published: December 19, 2014 ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, and in spite of intense efforts there are limited therapeutic options for patients with PDAC. PDACs harbor a high frequency of Kras mutations and other driver mutations that lead to altered signaling pathways and contribute to therapeutic resistance. Importantly, constitutive activation of nuclear factor κB (NF-κB) is frequently observed in PDAC. An increasing body of evidence suggests that both classical and non-classical NF-κB pathways play a crucial role in PDAC development and progression. In this review, we update the most recent advances regarding different aspects of NF-κB involvement in PDAC development and progression, emphasizing its potential as a therapeutic target and the need to discover pathway-specific cytosolic NF-κB regulators which could be used to design novel therapeutic strategies for PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727 · cited 1×
“Activation of NF-κB leads to the upregulation of RAGE expression in PDAC cells [35].”
BackgroundNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 1×
“PanIN is a crucial feature of PDAC initiation in humans and GEMMs, and PanIN progression to PDAC is accelerated by loss of tumor suppressor genes such as p53, Cdkn2A (cyclin-dependent kinase inhibitor 2A), Smad4 (mothers against decapentaplegic homolog 4), Pten (phosphatase and tensin homolog), or Rb (retinoblastoma p…”
BackgroundBardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674 · cited 1×
“PanIN is a crucial feature of PDAC initiation in humans and GEMMs, and PanIN progression to PDAC is accelerated by loss of tumor suppressor genes such as p53, Cdkn2A (cyclin-dependent kinase inhibitor 2A), Smad4 (mothers against decapentaplegic homolog 4), Pten (phosphatase and tensin homolog), or Rb (retinoblastoma p…”
Background
Cited by
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Peng, J., Sun, B.-F., Chen, C.-Y., Zhou, J.-Y., Chen, Y.-S., Chen, H., Liu, L., Huang, D., Jiang, J., Cui, G.-S., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0195-y · Cited by 1,321
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
Metadata
- Authors
- Prabhu, L., Mundade, R., Korc, M., Loehrer, P. J., & Lu, T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-11-30
- Volume
- 5
- Issue
- 22
- Pages
- 10969-10975
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2143192323
- Cited by
- 148
- References
- 7
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Critical role of NF-κB in pancreatic cancer. https://app.cochat.ai/papers/10.18632/oncotarget.2624
- The paper
- Prabhu, L., Mundade, R., Korc, M., Loehrer, P. J., & Lu, T. (2014). Critical role of NF-κB in pancreatic cancer. Oncotarget. https://doi.org/10.18632/oncotarget.2624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.